For healthcare professionals

This website is a global information resource. It is intended for healthcare professionals outside of the United States of America (US) and the United Kingdom (UK) who are interested in information on VABYSMO®. This website is not country-specific and therefore may contain information which is not applicable to your country. Please refer to your local Prescribing Information for full details.

VEGF-A and Ang-2 drive retinal vascular disease together^1-5

Start with the power of dual pathway inhibition^1,6,7

VABYSMO is the first approved bispecific antibody uniquely engineered to block two key pathways driving retinal vascular disease^1,6-9

Fc region: Fragment crystallisable region is the tail region of the antibody

References

Regula JT, et al. EMBO Mol Med. 2016;8:1265–88.
Augustin AJ, et al. Clin Ophthalmol. 2009;3:175–82.
Heier JS, et al. Retina. 2021;41:1–19.
Joussen AM, et al. Eye (Lond). 2021;35:1305–16.
Larsen HO, et al. Ophth Ther. 2023;12:2253–64.
Heier JS, et al. Lancet. 2022;399:729–40.
Wykoff CC, et al. Lancet. 2022;399:741–55.
VABYSMO®. SmPC https://go.roche.com/Vabysmo_SmPC Accessed May 2024
VABYSMO®. Prescribing Information. https://www.gene.com/download/pdf/vabysmo_prescribing.pdf Accessed May 2024

This website contains information on products that is targeted to a wide range of audiences, and may contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration or usage in your country of origin.

This website is a global information resource for a public audience, outside of the United States of America and the United Kingdom. This website is produced by Roche and is not intended to provide medical advice and/or treatment guidance. The content on this website is non-promotional and does not make specific reference to the availability or the use of a medicine.

▼ This medicinal product is subject to additional monitoring.

For healthcare professionals

VEGF-A and Ang-2 drive retinal vascular disease together1-5

Start with the power of dual pathway inhibition1,6,7

VABYSMO is the first approved bispecific antibody uniquely engineered to block two key pathways driving retinal vascular disease1,6-9

VEGF-A and Ang-2 drive retinal vascular disease together^1-5

Start with the power of dual pathway inhibition^1,6,7

VABYSMO is the first approved bispecific antibody uniquely engineered to block two key pathways driving retinal vascular disease^1,6-9